

Development 139, 1931–1940 (2012) doi:10.1242/dev.069377
 © 2012. Published by The Company of Biologists Ltd

Wnt5a and Wnt11 are essential for second heart field progenitor development

Ethan David Cohen^{1,*}, Mayumi F. Miller², Zichao Wang¹, Randall T. Moon³ and Edward E. Morrisey^{2,4,5,6,*}

SUMMARY

Wnt/ β -catenin has a biphasic effect on cardiogenesis, promoting the induction of cardiac progenitors but later inhibiting their differentiation. Second heart field progenitors and expression of the second heart field transcription factor *Islet1* are inhibited by the loss of β -catenin, indicating that Wnt/ β -catenin signaling is necessary for second heart field development. However, expressing a constitutively active β -catenin with *Islet1*-Cre also inhibits endogenous *Islet1* expression, reflecting the inhibitory effect of prolonged Wnt/ β -catenin signaling on second heart field development. We show that two non-canonical Wnt ligands, *Wnt5a* and *Wnt11*, are co-required to regulate second heart field development in mice. Loss of *Wnt5a* and *Wnt11* leads to a dramatic loss of second heart field progenitors in the developing heart. Importantly, this loss of *Wnt5a* and *Wnt11* is accompanied by an increase in Wnt/ β -catenin signaling, and ectopic *Wnt5a*/*Wnt11* inhibits β -catenin signaling and promotes cardiac progenitor development in differentiating embryonic stem cells. These data show that *Wnt5a* and *Wnt11* are essential regulators of the response of second heart field progenitors to Wnt/ β -catenin signaling and that they act by restraining Wnt/ β -catenin signaling during cardiac development.

KEY WORDS: Wnt, Cardiac development, Progenitor, Mouse

INTRODUCTION

The heart arises from two domains of lateral mesoderm that join at the anterior midline to form a crescent-shaped swathe of cardiogenic mesoderm under the head folds known as the cardiac crescent (Dyer and Kirby, 2009; Watanabe and Buckingham, 2010). The cardiac crescent contains two distinct fields of cardiac progenitors. The first heart field (FHF) occupies the medial region of the crescent and will coalesce at the ventral midline to form the initial linear heart tube, which is fated to become the myocardium of the left ventricle (LV). The second heart field (SHF) occupies more lateral regions of the crescent that are shifted dorsally into the pharyngeal mesenchyme as the heart tube fuses. SHF progenitors remain undifferentiated in the pharyngeal mesenchyme until later in development, when they migrate into the heart and contribute the majority of cardiomyocytes in the right ventricle (RV) and atria. How SHF progenitors and their derivatives differ from those of the FHF is poorly understood, but this knowledge will be crucial in our understanding of congenital heart defects and the potential differences in populations of cardiomyocytes derived from pluripotent stem cells.

Wnt proteins are secreted ligands that regulate diverse cellular behaviors and play pivotal roles in the development of cardiac progenitors (Tzahor, 2007; Cohen et al., 2008; Tian et al., 2010a). The canonical Wnt pathway stabilizes β -catenin and allows it to

enter the nucleus, where it complexes with TCF family DNA-binding proteins to activate gene transcription (Molenaar et al., 1996; Brunner et al., 1997; Korinek et al., 1998; Young et al., 1998). Experiments performed on embryonic stem (ES) cell-derived embryoid bodies (EBs) and zebrafish embryos have revealed at least two temporally distinct roles for Wnt/ β -catenin signaling during cardiogenesis (Naito et al., 2006; Ueno et al., 2007). The first phase promotes the induction of cardiac progenitors, whereas the second phase inhibits the maintenance of cardiac progenitor fate. SHF-specific β -catenin deletion reduces the numbers of SHF progenitors and their expression of the crucial SHF transcription factor *Islet1* (*Isl1*) in mouse embryos, indicating that canonical Wnt signaling is required in SHF cells (Ai et al., 2007; Cohen et al., 2007; Klaus et al., 2007; Kwon et al., 2007). However, forced activation of β -catenin signaling in *Isl1*⁺ cells also disrupts SHF development, confirming that canonical Wnt signaling plays both positive and negative roles in *Isl1*⁺ SHF progenitors (Kwon et al., 2009).

Wnt proteins can also activate Rho family GTPases and intracellular Ca²⁺ release to affect cytoskeletal organization, adhesion and motility (Malbon, 2004; James et al., 2008; Schlessinger et al., 2009). This non-canonical Wnt signaling also inhibits Wnt/ β -catenin signaling in many contexts and the balance between these activities may fine-tune the effects of Wnt proteins on responding cells (Torres et al., 1996; Ishitani et al., 1999; Ishitani et al., 2003; Mikels and Nusse, 2006; Yuan et al., 2011). *Wnt5a* and *Wnt11* promote cardiogenesis in frog and chick embryos as well as in differentiating stem cells through the non-canonical Wnt pathways (Eisenberg and Eisenberg, 1999; Schneider and Mercola, 2001; Pandur et al., 2002; Terami et al., 2004; Koyanagi et al., 2005; Koyanagi et al., 2009). Although these data suggest that *Wnt5a* and *Wnt11* act in early cardiac progenitors, *Wnt5a* and *Wnt11* mutations cause mild heart defects due to problems in cell-cell adhesion and cytoskeleton organization in differentiating cardiomyocytes (Schleiffarth et al., 2007; Zhou et al., 2007; Nagy et al., 2010). Here we show

¹Department of Medicine, Division of Endocrinology, University of Rochester, Rochester, NY 14642, USA. ²Howard Hughes Medical Institute, Institute for Stem Cell and Regenerative Medicine, Department of Pharmacology, University of Washington School of Medicine, Seattle, WA 98195, USA. ³Department of Cell and Developmental Biology, ⁴Department of Medicine, ⁵Institute for Regenerative Medicine and ⁶Cardiovascular Institute, University of Pennsylvania, Philadelphia, PA 19104, USA.

*Authors for correspondence (ethan_cohen@urmc.rochester.edu; emorrise@mail.med.upenn.edu)

that *Wnt5a* and *Wnt11* are co-required to restrain the inhibitory effects of prolonged canonical Wnt signaling on *Isl1*⁺ SHF progenitors.

MATERIALS AND METHODS

Generation of *Wnt5a*; *Wnt11* double-mutant mice

Mice carrying previously published alleles of *Wnt5a* and *Wnt11* (Yamaguchi et al., 1999; Majumdar et al., 2003) were intercrossed to produce double-mutant, single-mutant and wild-type embryos. To examine Wnt/β-catenin signaling in vivo, *Wnt5a*^{-/-}; *Wnt11*^{-/-} mice were crossed into the BAT-GAL strain, which carries a TCF-responsive *lacZ* reporter (Maretto et al., 2003). Genotyping for *Wnt5a*, *Wnt11* and BAT-GAL was performed as described (Yamaguchi et al., 1999; Majumdar et al., 2003; Maretto et al., 2003). All protocols were approved by the University of Pennsylvania Institutional Animal Care and Use Committee.

Histology

Embryos were fixed in 4% PFA overnight before being embedded and sectioned. Staining with *Isl1* (University of Iowa Hybridoma Bank, 40.2D6), *Nkx2.5* (Santa Cruz, sc-8697) and *Ki67* (DAKO, m7249) antibodies as well as TUNEL staining were performed as described (Cohen et al., 2007; Zhang et al., 2008) and examined with a confocal microscope. Labeling indexes for sections stained for *Isl1*, *Nkx2.5*, *Ki67* and TUNEL were obtained by dividing the number of labeled cells by the total number of cells within the fame. Graphs represent the average value of indexes from images of three embryos of each genotype. Error bars represent s.d. *P*<0.05 by Student's *t*-test indicated statistical significance.

In situ hybridization was performed as described (Cohen et al., 2007; Zhang et al., 2008). Probes were amplified from *Wnt5a* and *Wnt11* cDNAs (Open Biosystems) using the primers listed in supplementary material Table S1.

Generation and culture of EBs

TL1 mouse ES cells were grown on inactivated mouse embryonic fibroblasts in DMEM with 15% FBS (Hyclone) and LIF (Millipore ESGRO). To initiate differentiation, cells were dissociated, suspended at 5×10⁴ cells/ml in LIF-free media containing 100 μg/ml ascorbic acid and used to make 20 ml droplets on Petri dish lids. Cells were cultured as hanging drops for 2 days to form EBs, which were then cultured in poly-HEMA (Sigma-Aldrich)-treated dishes for another 2 days. On day 4, EBs were transferred to gelatin (Sigma-Aldrich)-coated dishes containing control media, media with 200 ng/ml mouse *Wnt5a* and/or human WNT11 (R&D Systems), or media with 200 ng/ml human WNT3A (R&D Systems). EBs were cultured with *meBIO* (50 nM, Millipore), *BIO* (50 nM, Millipore) or *XAV-939* (25 nM, Cayman Chemical) between days 4 and 6 of differentiation. The phosphorylation mutant form of active β-catenin (pCMV-act-β-catenin) has been reported previously (Provost et al., 2003). Additional groups of EBs were lysed on days 8, 10 and 12 for RNA isolation to detect Wnt and cardiac gene expression. ES cells were transfected with either pCMV-*lacZ* or pCMV-act-β-catenin using Effectine (Qiagen) as previously described (Ko et al., 2009; Liou et al., 2010).

Measuring TCF activity in EBs

EBs were made from ES cells transduced with pBarls, a TCF-responsive firefly luciferase virus (Fueller and Nusse, 2010), and with a constitutive Renilla luciferase virus. On day 4, EBs were placed in gelatin-coated dishes containing either control media or media with 250 ng/ml *Wnt5a* and/or WNT11. After 24 hours, luciferase activity was assayed with the Dual Luciferase Assay System (Promega). Renilla luciferase activity was used to normalize for transduction efficiency. Reported values are the mean ± s.e.m. for the normalized pBarls activity from at least three assays. *P*<0.05 by two-tailed Student's *t*-test indicated statistical significance.

Quantitative PCR (Q-PCR) and western blotting

Relative gene expression was calculated by the ΔCT method using *Gapdh* as an endogenous control. For Q-PCR analysis of embryonic hearts, graphs represent the average results from three independent pools of RNA isolated from the heart-containing regions, defined as the first pharyngeal arch to the septum transversum, of at least five embryos. For Q-PCR analysis of

EBs, graphs represent the average values from three pools of RNA isolated from independent experiments. RNA was reverse transcribed using Superscript III reverse transcriptase (Invitrogen) and Q-PCR performed on an ABI 7900 Cyclor with SYBR Green (Applied Biosystems) and the primers listed in supplementary material Table S1. The ΔCT values of all samples were normalized to the average ΔCT of control samples, thus allowing the standard deviation to be calculated from the ΔCT values of individual controls. Error bars represent s.d. *P*<0.05 by Student's *t*-test indicated statistical significance.

For western blotting, cells were collected 48 hours following transfection, lysed, and nuclear and cytoplasmic fractions were generated as described (Wang et al., 2005). Proteins were resolved on SDS-PAGE gels and transferred to PVDF membranes. Antibodies used in western blotting include: β-catenin (BD Transduction Laboratories), *Gapdh* (Abcam) and hnRNP (Santa Cruz).

RESULTS

Wnt5a and *Wnt11* are co-expressed at the anterior pole of the heart tube

In situ hybridization was performed to determine whether *Wnt5a* and *Wnt11* expression domains overlap in the embryonic heart, which could suggest a shared role in early cardiac development. We performed in situ hybridization for *Wnt5a* and *Wnt11* on sections of E7.5 embryos. Expression of *Wnt5a* was observed in the allantois, as has previously been reported, but expression of *Wnt5a* or *Wnt11* was not detected in the cardiac mesoderm at this stage (Fig. 1A,E) (Yamaguchi et al., 1999). By E8.5, *Wnt5a* and *Wnt11* were both expressed in the presumptive outflow tract (OFT) and RV and at lower levels in the LV and atria, similar to what has been reported previously (Fig. 1B-D,F-H) (Kispert et al., 1996; Yamaguchi et al., 1999; Terami et al., 2004). Co-expression of *Wnt5a* and *Wnt11* was maintained at the anterior pole of the heart until E10.5, at which time the patterns of *Wnt5a* and *Wnt11* expression began to diverge. *Wnt5a* became enriched in the mesoderm surrounding the branchial arch arteries and the laryngeal-tracheal groove as well as the medial layer of the OFT wall (Fig. 1I). *Wnt5a* expression continued in the compact myocardium of the RV, LV and atria (Fig. 1J). By contrast, *Wnt11* was expressed in both the inner and outer layers of the OFT wall and inner lining of the OFT cushion (Fig. 1K). Within the developing RV, LV and atria, *Wnt11* was expressed in the epicardium and endocardium, with the highest levels of expression observed in the epicardial cells surrounding the atria and inner lining of the endocardial cushions (Fig. 1L). *Wnt11* was also expressed in the endothelium of the arch arteries (Fig. 1K, arrowhead) and in the mesenchyme surrounding the trachea (Fig. 1L, asterisk).

Wnt5a and *Wnt11* are co-required for cardiac development

The overlap between *Wnt5a* and *Wnt11* expression in the OFT and RV of the embryonic heart suggested that these ligands play redundant roles in cardiac development. To test this hypothesis, mice carrying null alleles of *Wnt5a* and *Wnt11* (Yamaguchi et al., 1999; Majumdar et al., 2003) were intercrossed to generate *Wnt5a*^{-/-}; *Wnt11*^{-/-} embryos, as well as wild-type and single-mutant controls. Intriguingly, whereas *Wnt5a*^{-/-} and *Wnt11*^{-/-} embryos survived until birth, no *Wnt5a*^{-/-}; *Wnt11*^{-/-} embryos were found after E10.5. *Wnt5a*^{-/-}; *Wnt11*^{-/-} embryos were found at the expected Mendelian ratios in litters harvested at E9.5 and had beating hearts, indicating that *Wnt5a*^{-/-}; *Wnt11*^{-/-} embryos were viable at this stage.




Fig. 1. Expression of *Wnt5a* and *Wnt11* during mouse early cardiac development. (A) In situ hybridization showing *Wnt5a* expression in the allantois (asterisk) at E7.5 but not in the precardiac mesoderm (arrow). (B-D) Expression of *Wnt5a* is observed in the developing OFT and right ventricle myocardium at E8.5. (E-H) Expression of *Wnt11* is not observed in the early precardiac mesoderm at E7.5 (arrow) and only at low levels in the allantois. Expression of *Wnt11* is observed in the developing OFT and right ventricle myocardium at E8.5. (I,J) *Wnt5a* expression is observed in OFT mesenchyme (I, arrows) and the branchial arch region at E10.5 (I, arrowhead) and also in the ventricular and atrial myocardium (J, arrows) at E10.5. (K,L) *Wnt11* expression is observed in the myocardium of the OFT (K, arrows) and at lower levels in the atrioventricular region and atrial myocardium (L, arrows) at E10.5. Expression of *Wnt11* is observed diffusely and at low levels in ventricular myocardium at E10.5 (L). OFT, outflow tract; LV, left ventricle; RV, right ventricle. Scale bars: 50 μ m in A-H; 100 μ m in I-L.

To assess the extent of disruption to cardiac development by loss of *Wnt5a* and *Wnt11* expression, wild-type, *Wnt5a*^{-/-}, *Wnt11*^{-/-} and *Wnt5a*^{-/-}; *Wnt11*^{-/-} double-mutant embryos were harvested at E9.5 and processed for histological sectioning. Examining sections from anterior to posterior reveals severe cardiovascular defects in *Wnt5a*^{-/-}; *Wnt11*^{-/-} double-mutant embryos. *Wnt5a*^{-/-}; *Wnt11*^{-/-} embryos had a centrally located OFT leading to a single sac-like heart chamber that connects directly to the dorsal mesocardium at the posterior pole of the heart (Fig. 2Da-e). Although morphological abnormalities were apparent in *Wnt5a*^{-/-} and *Wnt11*^{-/-} hearts, these single-mutant hearts displayed evidence of chamber septation and development similar to wild-type hearts (Fig. 2Aa-d, Ba-e, Ca-e). By contrast, no chamber septation was apparent in *Wnt5a*^{-/-}; *Wnt11*^{-/-} hearts (Fig. 2Da-e). The OFT and RV of *Wnt5a*^{-/-} hearts appeared dilated and dysmorphic relative to those of wild-type hearts (Fig. 2Ba-c), whereas the OFT and RV of *Wnt11*^{-/-} hearts were small relative to those of controls (Fig. 2Ca-d). Although atrioventricular (AV) canal development was apparent in *Wnt5a*^{-/-} and *Wnt11*^{-/-} single mutants (Fig. 2Bc,d, Cc,d), no obvious AV canal development occurred in *Wnt5a*^{-/-}; *Wnt11*^{-/-} hearts (Fig. 2Da-e).

Development of SHF cardiac progenitors requires *Wnt5a* and *Wnt11*

Wnt5a and *Wnt11* are co-expressed in the presumptive OFT and LV, and the single-chambered phenotype of *Wnt5a*^{-/-}; *Wnt11*^{-/-} hearts was highly reminiscent of the cardiac defects found in *Isl1* mutants, suggesting that *Wnt5a* and *Wnt11* act together to promote the development of SHF cardiac progenitors (Cai et al., 2003). To determine whether the numbers of *Isl1*⁺ SHF progenitors were reduced in *Wnt5a*^{-/-}; *Wnt11*^{-/-} embryos, sections of E9.5 double-mutant, single-mutant and wild-type embryos were stained for *Isl1* protein expression. Although nearly 40% of cells in the OFT and pharyngeal mesenchyme of wild-type and single-mutant control embryos were *Isl1*⁺, less than 10% of these cells stained for *Isl1* in *Wnt5a*^{-/-}; *Wnt11*^{-/-} embryos (Fig. 3A-D,I). Furthermore, the *Isl1*⁺ cells in *Wnt5a*^{-/-}; *Wnt11*^{-/-} embryos stained much less intensely than those in wild-

type and single-mutant controls (Fig. 3A-D). By contrast, staining for *Nkx2.5*, which marks both FHF and SHF cardiac progenitors, was similar in all genotypes tested (Fig. 3E-I).

To further quantify FHF and SHF gene expression, Q-PCR from E9.5 embryos. Consistent with the results for *Isl1* and *Nkx2.5* immunostaining, *Isl1* mRNA levels were more than 80% lower in *Wnt5a*^{-/-}; *Wnt11*^{-/-} embryos than in wild-type and single-mutant controls, whereas the levels of *Nkx2.5* mRNA were unaffected (Fig. 3J). Like *Isl1*, the basic helix-loop-helix transcription factor *Hand2* is expressed in the SHF and is crucial for its development (Tsuchihashi et al., 2011), whereas expression of the highly related *Hand1* is restricted to the FHF and its derivatives (Riley et al., 1998; Thomas et al., 1998). Consistent with the loss of *Isl1* expression in *Wnt5a*^{-/-}; *Wnt11*^{-/-} embryos, *Hand2* expression was significantly reduced in double-mutant embryos, whereas *Hand1* expression was unaffected (Fig. 3J). These data indicate that *Wnt5a* and *Wnt11* are required for the development of SHF cardiac progenitors.

Cardiac development was also assessed at E8.5 to determine whether there were any early defects associated with cardiac progenitor development, proliferation or apoptosis in *Wnt5a*^{-/-}; *Wnt11*^{-/-} embryos. Although the *Wnt5a*^{-/-}; *Wnt11*^{-/-} embryos were smaller than single-mutant or wild-type controls at E9.5, *Wnt5a*^{-/-}; *Wnt11*^{-/-} embryos collected at E8.5 were similar in size and gross morphology to their wild-type and single-mutant littermates (Fig. 3K-N). *Wnt5a*^{-/-}; *Wnt11*^{-/-} hearts at E8.5 had a centrally aligned OFT that connected to a single cardiac chamber (Fig. 3M,N). Moreover, there was little AV canal development in *Wnt5a*^{-/-}; *Wnt11*^{-/-} embryos at E8.5 (Fig. 3M,N). Similar to the E9.5 embryos, *Isl1* expression was reduced but *Nkx2.5* expression was unaffected in E8.5 *Wnt5a*^{-/-}; *Wnt11*^{-/-} embryos, consistent with abnormal OFT and ventricular development observed at this stage (Fig. 3O-R,W).

To assess proliferation in *Wnt5a*^{-/-}; *Wnt11*^{-/-} hearts at E8.5, Ki67 immunostaining was performed. These data show increased proliferation in *Wnt5a*^{-/-}; *Wnt11*^{-/-} embryos in areas corresponding to the SHF (Fig. 3S,T,W). By contrast, TUNEL staining did not reveal any changes in apoptosis in *Wnt5a*^{-/-}; *Wnt11*^{-/-} embryos at




Fig. 2. *Wnt5a*^{-/-}; *Wnt11*^{-/-} embryos develop a single-chamber heart.

Hematoxylin and Eosin (H+E) staining of histological sections at E9.5 of (Aa-e) *Wnt5a*^{+/+}; *Wnt11*^{+/+}, (Ba-e) *Wnt5a*^{-/-}; *Wnt11*^{+/+}, (Ca-e) *Wnt5a*^{+/+}; *Wnt11*^{-/-} and (Da-e) *Wnt5a*^{-/-}; *Wnt11*^{-/-} mouse embryos. Wild type as well as *Wnt5a*^{-/-} and *Wnt11*^{-/-} mutants display proper chamber septation. However, *Wnt5a*^{-/-}; *Wnt11*^{-/-} mutants lack chamber septation and form a single-chamber heart (question mark in D). Arrows indicate where branchial arch arteries flow into the OFT of the heart. AT, atrium. Scale bar: 150 μ m.

E8.5 (Fig. 3U-W). Taken together, these data suggested that the loss of *Isl1*⁺ cells in *Wnt5a*^{-/-}; *Wnt11*^{-/-} embryos reflected a co-requirement of *Wnt5a*/*Wnt11* signaling in SHF development and is not the result of either a broad developmental delay or changes in the survival of cells within the SHF.

Since *Isl1*⁺ progenitors contribute to all of the major cell types within the heart, markers of myocardial and non-myocardial cell populations within the heart were examined to determine whether these cell types are affected in *Wnt5a*^{-/-}; *Wnt11*^{-/-} embryos. Immunostaining for the endothelial marker *Flk1* (*Kdr* – Mouse Genome Informatics) was unaffected in E8.5 *Wnt5a*^{-/-}; *Wnt11*^{-/-} embryos relative to controls (Fig. 3X,Y). Q-PCR revealed that mRNA levels for the endothelial markers *Flk1* and *Cd31* (*Pecam1* – Mouse Genome Informatics) and smooth muscle markers smooth muscle α -actin (*Acta2*) and *Sm22a* (*Tagln* – Mouse Genome Informatics) were unaffected in the hearts of *Wnt5a*^{-/-}; *Wnt11*^{-/-} embryos (Fig. 3Z). By contrast, expression of the myocardial-specific markers *cTnI* (*Tnni3* – Mouse Genome Informatics) and *Mlc2v* (*Myl2* – Mouse Genome Informatics) was significantly reduced in *Wnt5a*^{-/-}; *Wnt11*^{-/-} embryos (Fig. 3Z).

Taken together, these data suggest that the myocardial differentiation of *Isl1*⁺ SHF progenitors is specifically affected by the combined loss of *Wnt5a* and *Wnt11*.

***Wnt5a* and *Wnt11* are co-required to induce cardiac progenitor gene expression in differentiating ES cells**

To examine the temporal relationship between *Wnt5a* and *Wnt11* expression and cardiac differentiation, EBs were formed from mouse ES cells using the hanging drop method and used to

assess expression of various Wnt proteins. Expression of *Wnt3a* and *Wnt5a*, which are both expressed in the primitive streak, first began to rise on day 4 of EB differentiation and increased steadily, hitting a peak on days 8 and 10, respectively, and declining thereafter (Fig. 4A,B) (Yamaguchi et al., 1999; Baranski et al., 2000). By contrast, *Wnt11* expression increased slowly between days 0 and 8 before it increased abruptly on day 10 and remained high through day 14 of EB differentiation (Fig. 4C). To compare the timing of *Wnt5a* and *Wnt11* expression with the appearance of cardiac progenitor gene expression, the percentage maximum expression for *Wnt5a*, *Wnt11*, *Isl1*, *Nkx2.5* and the precardiac mesoderm marker *Mesp1* was plotted over the course of EB differentiation (Fig. 4D). This comparison shows that expression of *Wnt5a* roughly coincided with markers of early cardiac mesoderm including *Isl1*, *Nkx2.5* and *Mesp1*, whereas *Wnt11* expression increased somewhat later.

To determine whether *Wnt5a* and *Wnt11* could induce markers of early cardiac mesoderm progenitors, EBs were formed as hanging drops and allowed to develop until day 4, the point at which *Mesp1*⁺ cardiac competent mesoderm first appears (Bondué et al., 2008). EBs were then cultured in either control media, media containing recombinant *Wnt5a* and/or *Wnt11* proteins or media containing recombinant WNT3A protein and Q-PCR used to measure gene expression. Since Wnt/ β -catenin signaling was previously shown to promote the formation of cardiac competent mesoderm, we first examined the expression of *Mesp1*, a helix-loop-helix transcription factor expressed in early precardiac mesoderm and the cardiac crescent but later extinguished as the heart tube develops (Saga et al., 1999; Kitajima et al., 2000; Saga et al., 2000; Lindsley et al., 2006;




Fig. 3. Wnt5a and Wnt11 are necessary for SHF progenitor development and myocardial differentiation. (A-D) Immunostaining shows that Islet1 protein expression (arrows) is dramatically reduced in *Wnt5a*^{-/-}; *Wnt11*^{+/+} mouse embryos compared with wild type or single mutants. (E-H) By contrast, Nkx2.5 protein expression (arrows) is not significantly altered in *Wnt5a*^{-/-}; *Wnt11*^{+/+} mutants compared with wild type and single mutants. (I) Quantitation of Islet1⁺ cells in single and double mutants. (J) Q-PCR shows that expression of *Islet1* and *Hand2* is reduced in *Wnt5a*^{-/-}; *Wnt11*^{-/-} mutants, whereas *Nkx2.5* and *Hand1* expression is not altered. (K-N) H+E-stained sections of wild type and *Wnt5a*^{-/-}; *Wnt11*^{-/-} mutants at E8.5 showing lack of chamber septation in the *Wnt5a*^{-/-}; *Wnt11*^{-/-} heart. Question mark indicates single-chamber heart. (O-R) Islet1 (O,P) and Nkx2.5 (Q,R) immunostaining at E8.5 in wild type and *Wnt5a*^{-/-}; *Wnt11*^{-/-} mutants. (S-V) Ki67 (S,T) and Nkx2.5 (U,V) immunostaining at E8.5 in wild type and *Wnt5a*^{-/-}; *Wnt11*^{-/-} mutants. (W) Quantitation of Islet1⁺, Nkx2.5⁺, Ki67⁺ and TUNEL⁺ cells in wild type and *Wnt5a*^{-/-}; *Wnt11*^{-/-} mutants. (X,Y) Flk1 immunostaining in wild type (X) and *Wnt5a*^{-/-}; *Wnt11*^{-/-} mutants (Y). (Z) Q-PCR for *Mlc2v*, *cTnl*, smooth muscle α -actin, *Flk1* and *Cd31* in wild type and *Wnt5a*^{-/-}; *Wnt11*^{-/-} mutants. *P*<0.05 by Student's *t*-test indicates statistical significance. DKO, double knockout. Error bars indicate s.e.m. Scale bars: 50 μ m in A-H; 150 μ m in K-N; 100 μ m in O-V,X,Y.

Lindsley et al., 2008). Treatment with Wnt5a, WNT11 or WNT3A individually caused a ~50% increase in peak *Mesp1* expression relative to controls, and treatment with Wnt5a and WNT11 together caused only a slight increase in *Mesp1* expression relative to treatment with either Wnt alone (Fig. 4E). By contrast, expression of *Tbx5*, which is expressed in the precardiic mesoderm and cardiac crescent before being restricted to the venous pole of the heart (Bruneau et al., 1999), is increased in EBs treated with Wnt5a and WNT11 together as compared with those treated with Wnt5a, WNT11 or WNT3A

alone (Fig. 4F). Most importantly, combined Wnt5a WNT11 treatment also caused cooperative increases in the levels of both *Nkx2.5* and *Islet1* expression over the levels of expression found in either control EBs or those treated with Wnt5a, WNT11 or WNT3A alone (Fig. 4G,H). This increase in *Nkx2.5* could be the result of an expansion of early precardiic mesoderm by Wnt5a and WNT11 that leads to an overall increase in cardiogenesis.

Taken together, these data suggest that Wnt5a and Wnt11 are co-required to increase both FHF and SHF progenitor markers during EB differentiation.




Fig. 4. Wnt5a and Wnt11 cooperatively promote early cardiac progenitor development in differentiating ES cells.

(A-D) Temporal expression of *Wnt3a* (A), *Wnt5a* (B) and *Wnt11* (C) in mouse ES cell-derived embryoid body (EB) cultures at the days indicated. Overlay of temporal expression patterns of *Wnt5a*, *Wnt11*, *Mesp1*, *Isl1* and *Nkx2.5* (D). (E-H) Q-PCR analysis showing effects of recombinant WNT3A, Wnt5a, WNT11, or Wnt5a plus WNT11 on expression of *Mesp1* (E), *Tbx5* (F), *Isl1* (G) and *Nkx2.5* (H) in ES cell-derived EB cultures at the days indicated. Error bars indicate s.e.m.

Wnt5a and Wnt11 are co-required to repress canonical Wnt signaling in SHF progenitors

Although Wnt5a and Wnt11 are thought to signal via non-canonical pathways, they can also co-activate Wnt/ β -catenin signaling during early *Xenopus* development in a manner that is reminiscent of their cooperative regulation of *Isl1* and SHF development (Cha et al., 2008; Cha et al., 2009). To assess canonical Wnt signaling activity in the SHF of *Wnt5a*^{-/-}; *Wnt11*^{-/-} embryos, we crossed the BAT-GAL strain Wnt reporter line into the *Wnt5a*^{+/-}; *Wnt11*^{+/-} mutants (Maretto et al., 2003). Sections through the hearts of E9.5 embryos stained with X-gal reveal that the number of stained cells within the walls of the OFT and surrounding mesenchyme are increased in *Wnt5a*^{-/-}; *Wnt11*^{-/-} mutants relative to controls, suggesting that Wnt5a and Wnt11 are co-required to repress canonical Wnt signaling in the SHF (Fig. 5A,B).

A previous study identified several genes, including *Bhlhb2* (*Bhlhe40*), *Ndr1*, *Fgf11* and *Rora*, as being upregulated by β -catenin signaling in *Isl1*⁺ SHF progenitors (Kwon et al., 2009). To confirm that β -catenin signaling is increased in the SHF progenitors of *Wnt5a*^{-/-}; *Wnt11*^{-/-} embryos, the expression levels of these genes were examined by Q-PCR. These data show that levels of *Bhlhb2*, *Ndr1*, *Fgf11* and *Rora* mRNA were all dramatically increased in *Wnt5a*^{-/-}; *Wnt11*^{-/-} hearts relative to either single-mutant or wild-type controls, further indicating that β -catenin signaling is upregulated in double-mutant SHF progenitors (Fig. 5C-F).

Forced activation of β -catenin signaling blocks the effects of Wnt5a and Wnt11 on cardiac differentiation

The increased BAT-GAL activity in *Wnt5a*^{-/-}; *Wnt11*^{-/-} embryos suggested that Wnt5a and Wnt11 are normally co-required to attenuate canonical Wnt signaling in the SHF. To determine whether Wnt5a and Wnt11 are sufficient to inhibit canonical Wnt signaling, EBs were produced from ES cells transduced with the TCF-responsive luciferase reporter virus pBarls (Biechele et al., 2009). On day 4 of differentiation, these EBs were placed in control media as well as media containing recombinant Wnt5a, WNT11, or Wnt5a plus WNT11. After 24 hours, EBs were lysed and luciferase activities determined. Concordant with the increased levels of β -catenin signaling in *Wnt5a*^{-/-}; *Wnt11*^{-/-} embryos, treating EBs with media containing both Wnt5a and WNT11 caused a significant decrease in pBarls activity (Fig. 6A).

To further test the effects of activated Wnt/ β -catenin signaling on cardiac progenitor development in differentiating ES cells using the pBarls Wnt reporter, day-4 EBs were transferred to media containing combinations of the Gsk3 β inhibitor BIO, its inactive form meBIO, and Wnt5a and/or WNT11 proteins, for 48 hours. The combined action of Wnt5a and WNT11 inhibited pBarls Wnt reporter activity as expected in the presence of the inactive Gsk3 β inhibitor meBIO (Fig. 6B). However, in the presence of BIO, Wnt5a and WNT11 were unable to repress pBarls Wnt reporter activity (Fig. 6B). Q-PCR showed that activation of Wnt signaling




Fig. 5. Combined loss of Wnt5a and Wnt11 during mouse development increases canonical Wnt/ β -catenin signaling activity and SHF target gene expression. (A,B) BAT-GAL *lacZ* expression (arrows) is increased in *Wnt5a*^{-/-}; *Wnt11*^{-/-} mutants compared with wild-type controls. (C-F) Expression of *Bhlhb2* (C), *Rora* (D), *Ndrgr1* (E) and *Fgf11* (F) is increased in *Wnt5a*^{-/-}; *Wnt11*^{-/-} hearts but not single-mutant hearts. For all four genes, only the increased expression in the *Wnt5a*^{-/-}; *Wnt11*^{-/-} mutants was considered significant ($P < 0.01$). Error bars indicate s.e.m. Scale bars: 50 μ m.

by BIO inhibited the increase of *Isl1* and *Nkx2.5* gene expression caused by treatment of differentiating EBs with Wnt5a and WNT11 (Fig. 6C,D). Moreover, expression of an activated form of β -catenin containing mutations in the Gsk3 β phosphorylation sites during EB differentiation also inhibited the increase in *Isl1* and *Nkx2.5* cardiac gene expression in comparison to control *lacZ* expression (Fig. 6E,F).

To assess whether the combined action of Wnt5a and WNT11 affected additional readouts of canonical Wnt signaling, we performed western blots to assess the levels of nuclear β -catenin upon treatment of differentiating EBs. These data show that the combination of Wnt5a and WNT11 causes a decrease in nuclear β -catenin levels (Fig. 6G). Moreover, this decrease in β -catenin was not observed in the presence of BIO, consistent with the observed effects on the pBArts Wnt reporter above (Fig. 6H). Finally, to assess whether direct inhibition of Wnt/ β -catenin signaling could affect cardiac gene expression, we treated differentiating EBs with the tankyrase inhibitor XAV-939, which promotes axin-Gsk3 β interactions and thereby represses canonical Wnt signaling (Huang et al., 2009). Using this method, we observed a significant increase in *Isl1* and *Nkx2.5* gene expression (Fig. 6I). Thus, the ability of Wnt5a and Wnt11 to cooperatively repress β -catenin signaling in differentiating EBs is essential for their activation of cardiac gene expression and promotion of cardiac progenitor development.

DISCUSSION

The data presented here support a novel role for Wnt5a and Wnt11 in SHF development that is mediated by blocking the later inhibitory effect of Wnt/ β -catenin signaling on *Isl1*⁺ SHF progenitors. We show that *Wnt5a*^{-/-}; *Wnt11*^{-/-} embryos die early in embryogenesis and have single-chamber sac-like hearts reminiscent of those found in *Isl1*^{-/-} embryos. Moreover, expression of the SHF markers *Isl1* and *Hand2* is significantly reduced in *Wnt5a*^{-/-}; *Wnt11*^{-/-} embryos, whereas *Nkx2.5*, which is expressed in both FHF and SHF, is unaffected. Interestingly, treating EBs with Wnt5a and Wnt11 causes a strong cooperative increase in the expression of *Isl1*, as well as other early cardiac progenitor markers including *Nkx2.5*, that far exceeds those caused by either Wnt alone, and this

requires inhibition of β -catenin signaling. These data suggest that Wnt5a and Wnt11 are co-required to promote cardiogenesis, in part, through inhibition of β -catenin signaling.

Experiments in ES cells and zebrafish embryos indicate that canonical Wnt signaling plays two temporally distinct roles in cardiogenesis, first promoting the appearance of early precardiac mesoderm and then later inhibiting cardiac differentiation. Consistent with these data, the canonical Wnt ligand Wnt3a is sufficient to induce *Mesp1* expression in differentiating ES cells, but overexpressing *Mesp1* in ES cells promotes cardiac differentiation only if canonical Wnt signaling is simultaneously inhibited (Bondue et al., 2008). We were unable to detect either Wnt5a or Wnt11 in the cardiogenic mesoderm of E7.5 head-fold stage mouse embryos, which is consistent with the results of previous studies indicating that expression of Wnt11 in the heart begins at E8.0 (Kispert et al., 1996; Terami et al., 2004). These data suggest that reports of Wnt11 expression in the cardiac crescent of the chick embryo might reflect species-specific differences between avian and mammalian development or that Wnt11 expression is present in early precardiac mesoderm prior to heart tube formation but is dramatically upregulated upon fusion of the lateral cardiac primordia (Eisenberg and Eisenberg, 1999; Hardy et al., 2008). Our expression studies on Wnt5a and Wnt11 in E8.5 embryos revealed a previously unappreciated degree of overlap between the expression of these Wnt ligands in the presumptive OFT and RV at the anterior pole of the heart tube. Furthermore, although Wnt5a and Wnt11 expression no longer overlap in the mouse heart at E10.5, they are expressed in a complementary pattern that allows them to signal cooperatively in a paracrine fashion at this stage. Thus, the in vivo developmental role of Wnt5a and Wnt11 appears to be restricted to regulation of SHF progenitor development.

How Wnt5a and Wnt11 co-regulate early cardiac development is still unclear. Our data show that the combination of Wnt5a and Wnt11 mediates a decrease in nuclear β -catenin levels, which corresponds to a decrease in canonical Wnt activity. This function of Wnt5a and Wnt11 appears to act after the time period when Wnt3a induction of canonical Wnt signaling occurs in cardiogenesis in differentiating EBs. Previous studies have shown that Wnt5a and Wnt11 can dimerize to promote canonical Wnt




Fig. 6. Wnt5a and Wnt11 cooperatively inhibit Wnt/ β -catenin signaling activity in differentiating ES cells. (A) Recombinant Wnt5a and WNT11 in combination can repress Wnt/ β -catenin signaling in mouse EBs as shown using the Wnt/ β -catenin reporter pBArLs. (B) The Gsk3 β inhibitor BIO inhibits the repressive effects on Wnt/ β -catenin signaling caused by the combined addition of Wnt5a and WNT11 to EBs, whereas the inactive form meBIO does not. (C,D) Q-PCR analysis showing that addition of BIO inhibits the activation of *Is11* (C) and *Nkx2.5* (D) caused by co-treatment with Wnt5a and WNT11, whereas DMSO and meBIO have little effect. (E,F) Expression of an activated form of β -catenin inhibits the activation of *Is11* (E) and *Nkx2.5* (F) caused by co-treatment with Wnt5a and WNT11. (G) Western blot for expression of nuclear β -catenin showing that the combined action of Wnt5a and WNT11 decreases nuclear β -catenin levels in differentiating EBs. Sequestered protein expression of hnRNP and Gapdh show that the nuclear and cytoplasmic fractionation worked and that these fractions are relatively pure. (H) Western blot showing that nuclear levels of β -catenin could not be decreased by the combined action of Wnt5a and WNT11 in the presence of BIO. (I) Treatment of differentiating EBs with XAV-939 increases *Is11* and *Nkx2.5* expression. Decreases in pBArLs activity in A and B ($P < 0.05$), increases in *Is11* and *Nkx2.5* gene expression in C-F ($P < 0.005$) and the increase in *Is11* and *Nkx2.5* expression in I ($P < 0.001$) are significant. Error bars indicate s.e.m.

signaling in *Xenopus* (Cha et al., 2008). In cardiac development and in cardiogenesis in differentiating EBs, we observe an inhibition of nuclear β -catenin levels and canonical Wnt signaling activity. This discrepancy might simply reflect differences in the activity of these Wnt ligands in different developmental contexts. Interestingly, previous reports have shown that Wnt11 can promote cardiogenesis through caspase 3-mediated degradation of β -catenin that appears to be independent of the cytoplasmic destruction complex (Abdul-Ghani et al., 2011). Although we did not observe decreased nuclear β -catenin with treatment of EBs with Wnt11 alone, such a mechanism could still be active during the cardiogenesis promoted by the combination of Wnt5a and Wnt11.

Although *Is11*⁺ SHF progenitors are specifically affected in *Wnt5a*^{-/-}; *Wnt11*^{-/-} embryos, levels of *Tbx5*, *Nkx2.5* and *Is11* mRNAs are all dramatically increased in EBs treated with the combination of Wnt5a and Wnt11. Whereas *Nkx2.5* is expressed in SHF progenitors, *Tbx5* is not expressed in the SHF or its derivatives but rather in the LV and atria and is therefore considered a specific marker of the FHF (Bruneau et al., 1999). Given these data, the increased *Tbx5* expression in EBs treated with Wnt5a and Wnt11 suggests that cooperative signaling by these Wnt proteins might be sufficient to promote both FHF and SHF fates if present during early precardiac mesoderm development. These data are consistent with the results of studies of heart

development in *Xenopus*, which indicate that inhibition of canonical Wnt signaling is both necessary and sufficient for FHF formation (Schneider and Mercola, 2001). The ability of Wnt5a and Wnt11 to induce FHF markers including *Mesp1* and *Tbx5* occurs earlier than induction of SHF markers, suggesting that Wnt5a and Wnt11 might act via different mechanisms in a temporal-specific fashion during cardiogenesis. In the EB culture system, FHF and SHF progenitors are likely to co-develop at similar times and might be affected in the same fashion in gain-of-function experiments using exogenous Wnt ligands. Also, such differences are often observed between gain-of-function and loss-of-function experiments and might not be reflective of the physiological role for the specific Wnt ligands in question.

The endogenous factors responsible for inhibiting the negative effects of prolonged Wnt signaling during cardiac progenitor development have yet to be identified, and the mechanisms by which the activities of Wnt agonists and repressors are balanced in both FHF and SHF cardiac progenitors remain poorly understood. Additional research will be needed to determine how pathways that inhibit canonical signaling, such as the suppression of β -catenin signaling by Wnt5a/Wnt11, are balanced with the active promotion of Wnt/ β -catenin signaling in the heart by ligands such as Wnt3a, Wnt8a and Wnt2 (Tian et al., 2010b).

Funding

These studies were supported by funding from the National Institutes of Health [HL100405 and HL087825 to E.E.M.] and the American Heart Association Jon Holden DeHaan Myogenesis Center Grant (E.E.M.). E.D.C. is a recipient of an American Heart Association Scientist Development Grant. R.T.M. is an Investigator of the Howard Hughes Medical Institute. Deposited in PMC for release after 6 months.

Competing interests statement

The authors declare no competing financial interests.

Supplementary material

Supplementary material available online at <http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.069377/-DC1>

References

- Abdul-Ghani, M., Dufort, D., Stiles, R., De Repentigny, Y., Kothary, R. and Megeney, L. A. (2011). Wnt11 promotes cardiomyocyte development by caspase-mediated suppression of canonical Wnt signals. *Mol. Cell. Biol.* **31**, 163-178.
- Ai, D., Fu, X., Wang, J., Lu, M. F., Chen, L., Baldini, A., Klein, W. H. and Martin, J. F. (2007). Canonical Wnt signaling functions in second heart field to promote right ventricular growth. *Proc. Natl. Acad. Sci. USA* **104**, 9319-9324.
- Baranski, M., Berdoudo, E., Sandler, J. S., Darnell, D. K. and Burrus, L. W. (2000). The dynamic expression pattern of frzb-1 suggests multiple roles in chick development. *Dev. Biol.* **217**, 25-41.
- Biechele, T. L., Adams, A. M. and Moon, R. T. (2009). Transcription-based reporters of Wnt/beta-catenin signaling. *Cold Spring Harb. Protoc.* **2009**, pdb prot5223.
- Bondue, A., Lapouge, G., Paulissen, C., Semeraro, C., Iacovino, M., Kyba, M. and Blanpain, C. (2008). Mesp1 acts as a master regulator of multipotent cardiovascular progenitor specification. *Cell Stem Cell* **3**, 69-84.
- Bruneau, B. G., Logan, M., Davis, N., Levi, T., Tabin, C. J., Seidman, J. G. and Seidman, C. E. (1999). Chamber-specific cardiac expression of Tbx5 and heart defects in Holt-Oram syndrome. *Dev. Biol.* **211**, 100-108.
- Brunner, E., Peter, O., Schweizer, L. and Basler, K. (1997). pangolin encodes a Lef-1 homologue that acts downstream of Armadillo to transduce the Wingless signal in Drosophila. *Nature* **385**, 829-833.
- Cai, C. L., Liang, X., Shi, Y., Chu, P. H., Pfaff, S. L., Chen, J. and Evans, S. (2003). Isl1 identifies a cardiac progenitor population that proliferates prior to differentiation and contributes a majority of cells to the heart. *Dev. Cell* **5**, 877-889.
- Cha, S. W., Tadjuidje, E., Tao, Q., Wylie, C. and Heasman, J. (2008). Wnt5a and Wnt11 interact in a maternal Dkk1-regulated fashion to activate both canonical and non-canonical signaling in Xenopus axis formation. *Development* **135**, 3719-3729.
- Cha, S. W., Tadjuidje, E., White, J., Wells, J., Mayhew, C., Wylie, C. and Heasman, J. (2009). Wnt11/5a complex formation caused by tyrosine sulfation increases canonical signaling activity. *Curr. Biol.* **19**, 1573-1580.
- Cohen, E. D., Wang, Z., Lepore, J. J., Lu, M. M., Taketo, M. M., Epstein, D. J. and Morrissy, E. E. (2007). Wnt/beta-catenin signaling promotes expansion of Isl-1-positive cardiac progenitor cells through regulation of FGF signaling. *J. Clin. Invest.* **117**, 1794-1804.
- Cohen, E. D., Tian, Y. and Morrissy, E. E. (2008). Wnt signaling: an essential regulator of cardiovascular differentiation, morphogenesis and progenitor self-renewal. *Development* **135**, 789-798.
- Dyer, L. A. and Kirby, M. L. (2009). The role of secondary heart field in cardiac development. *Dev. Biol.* **336**, 137-144.
- Eisenberg, C. A. and Eisenberg, L. M. (1999). WNT11 promotes cardiac tissue formation of early mesoderm. *Dev. Dyn.* **216**, 45-58.
- Fuerer, C. and Nusse, R. (2010). Lentiviral vectors to probe and manipulate the Wnt signaling pathway. *PLoS ONE* **5**, e9370.
- Hardy, K. M., Garriock, R. J., Yatskevych, T. A., D'Agostino, S. L., Antin, P. B. and Krieg, P. A. (2008). Non-canonical Wnt signaling through Wnt5a/b and a novel Wnt11 gene, Wnt11b, regulates cell migration during avian gastrulation. *Dev. Biol.* **320**, 391-401.
- Huang, S. M., Mishina, Y. M., Liu, S., Cheung, A., Stegmeier, F., Michaud, G. A., Charlat, O., Wiellette, E., Zhang, Y., Wiessner, S. et al. (2009). Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. *Nature* **461**, 614-620.
- Ishitani, T., Ninomiya-Tsuji, J., Nagai, S., Nishita, M., Meneghini, M., Barker, N., Waterman, M., Bowerman, B., Clevers, H., Shibuya, H. et al. (1999). The TAK1-NLK-MAPK-related pathway antagonizes signalling between beta-catenin and transcription factor TCF. *Nature* **399**, 798-802.
- Ishitani, T., Kishida, S., Hyodo-Miura, J., Ueno, N., Yasuda, J., Waterman, M., Shibuya, H., Moon, R. T., Ninomiya-Tsuji, J. and Matsumoto, K. (2003). The TAK1-NLK mitogen-activated protein kinase cascade functions in the Wnt-5a/Ca(2+) pathway to antagonize Wnt/beta-catenin signaling. *Mol. Cell. Biol.* **23**, 131-139.
- James, R. G., Conrad, W. H. and Moon, R. T. (2008). Beta-catenin-independent Wnt pathways: signals, core proteins, and effectors. *Methods Mol. Biol.* **468**, 131-144.
- Kispert, A., Vainio, S., Shen, L., Rowitch, D. H. and McMahon, A. P. (1996). Proteoglycans are required for maintenance of Wnt-11 expression in the ureter tips. *Development* **122**, 3627-3637.
- Kitajima, S., Takagi, A., Inoue, T. and Saga, Y. (2000). MesP1 and MesP2 are essential for the development of cardiac mesoderm. *Development* **127**, 3215-3226.
- Klaus, A., Saga, Y., Taketo, M. M., Tzahor, E. and Birchmeier, W. (2007). Distinct roles of Wnt/beta-catenin and Bmp signaling during early cardiogenesis. *Proc. Natl. Acad. Sci. USA* **104**, 18531-18536.
- Ko, B. S., Chang, T. C., Shyue, S. K., Chen, Y. C. and Liou, J. Y. (2009). An efficient transfection method for mouse embryonic stem cells. *Gene Therapy* **16**, 154-158.
- Korinek, V., Barker, N., Willert, K., Molenaar, M., Roose, J., Wagenaar, G., Markman, M., Lamers, W., Destree, O. and Clevers, H. (1998). Two members of the Tcf family implicated in Wnt/beta-catenin signaling during embryogenesis in the mouse. *Mol. Cell. Biol.* **18**, 1248-1256.
- Koyanagi, M., Haendeler, J., Badorff, C., Brandes, R. P., Hoffmann, J., Pandur, P., Zeiher, A. M., Kuhl, M. and Dimmeler, S. (2005). Non-canonical Wnt signaling enhances differentiation of human circulating progenitor cells to cardiomyogenic cells. *J. Biol. Chem.* **280**, 16838-16842.
- Koyanagi, M., Iwasaki, M., Haendeler, J., Leitges, M., Zeiher, A. M. and Dimmeler, S. (2009). Wnt5a increases cardiac gene expressions of cultured human circulating progenitor cells via a PKC delta activation. *PLoS ONE* **4**, e5765.
- Kwon, C., Arnold, J., Hsiao, E. C., Taketo, M. M., Conklin, B. R. and Srivastava, D. (2007). Canonical Wnt signaling is a positive regulator of mammalian cardiac progenitors. *Proc. Natl. Acad. Sci. USA* **104**, 10894-10899.
- Kwon, C., Qian, L., Cheng, P., Nigam, V., Arnold, J. and Srivastava, D. (2009). A regulatory pathway involving Notch1/beta-catenin/Isl1 determines cardiac progenitor cell fate. *Nat. Cell Biol.* **11**, 951-957.
- Lindsley, R. C., Gill, J. G., Kyba, M., Murphy, T. L. and Murphy, K. M. (2006). Canonical Wnt signaling is required for development of embryonic stem cell-derived mesoderm. *Development* **133**, 3787-3796.
- Lindsley, R. C., Gill, J. G., Murphy, T. L., Langer, E. M., Cai, M., Mashayekhi, M., Wang, W., Niwa, N., Nerbonne, J. M., Kyba, M. et al. (2008). Mesp1 coordinately regulates cardiovascular fate restriction and epithelial-mesenchymal transition in differentiating ESCs. *Cell Stem Cell* **3**, 55-68.
- Liou, J. Y., Ko, B. S. and Chang, T. C. (2010). An efficient transfection method for mouse embryonic stem cells. *Methods Mol. Biol.* **650**, 145-153.
- Majumdar, A., Vainio, S., Kispert, A., McMahon, J. and McMahon, A. P. (2003). Wnt11 and Ret/Gdnf pathways cooperate in regulating ureteric branching during metanephric kidney development. *Development* **130**, 3175-3185.
- Malbon, C. C. (2004). Frizzleds: new members of the superfamily of G-protein-coupled receptors. *Front. Biosci.* **9**, 1048-1058.
- Maretto, S., Cordenonsi, M., Dupont, S., Braghetta, P., Broccoli, V., Hassan, A. B., Volpin, D., Bressan, G. M. and Piccolo, S. (2003). Mapping Wnt/beta-catenin signaling during mouse development and in colorectal tumors. *Proc. Natl. Acad. Sci. USA* **100**, 3299-3304.
- Mikels, A. J. and Nusse, R. (2006). Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. *PLoS Biol.* **4**, e115.
- Molenaar, M., van de Wetering, M., Oosterwegel, M., Peterson-Maduro, J., Godsave, S., Korinek, V., Roose, J., Destree, O. and Clevers, H. (1996). XTcf-3 transcription factor mediates beta-catenin-induced axis formation in Xenopus embryos. *Cell* **86**, 391-399.
- Nagy, I. I., Railo, A., Rapila, R., Hast, T., Sormunen, R., Tavi, P., Rasanen, J. and Vainio, S. J. (2010). Wnt-11 signalling controls ventricular myocardium development by patterning N-cadherin and beta-catenin expression. *Cardiovasc. Res.* **85**, 100-109.
- Naito, A. T., Shiojima, I., Akazawa, H., Hidaka, K., Morisaki, T., Kikuchi, A. and Komuro, I. (2006). Developmental stage-specific biphasic roles of Wnt/beta-catenin signaling in cardiomyogenesis and hematopoiesis. *Proc. Natl. Acad. Sci. USA* **103**, 19812-19817.
- Pandur, P., Lasche, M., Eisenberg, L. M. and Kuhl, M. (2002). Wnt-11 activation of a non-canonical Wnt signalling pathway is required for cardiogenesis. *Nature* **418**, 636-641.
- Provost, E., Yamamoto, Y., Lizardi, I., Stern, J., D'Aquila, T. G., Gaynor, R. B. and Rimm, D. L. (2003). Functional correlates of mutations in beta-catenin exon 3 phosphorylation sites. *J. Biol. Chem.* **278**, 31781-31789.
- Riley, P., Anson-Cartwright, L. and Cross, J. C. (1998). The Hand1 bHLH transcription factor is essential for placentation and cardiac morphogenesis. *Nat. Genet.* **18**, 271-275.
- Saga, Y., Miyagawa-Tomita, S., Takagi, A., Kitajima, S., Miyazaki, J. and Inoue, T. (1999). MesP1 is expressed in the heart precursor cells and required for the formation of a single heart tube. *Development* **126**, 3437-3447.

- Saga, Y., Kitajima, S. and Miyagawa-Tomita, S. (2000). Mesp1 expression is the earliest sign of cardiovascular development. *Trends Cardiovasc. Med.* **10**, 345-352.
- Schleiffarth, J. R., Person, A. D., Martinsen, B. J., Sukovich, D. J., Neumann, A., Baker, C. V., Lohr, J. L., Cornfield, D. N., Ekker, S. C. and Petryk, A. (2007). Wnt5a is required for cardiac outflow tract septation in mice. *Pediatr. Res.* **61**, 386-391.
- Schlessinger, K., Hall, A. and Tolwinski, N. (2009). Wnt signaling pathways meet Rho GTPases. *Genes Dev.* **23**, 265-277.
- Schneider, V. A. and Mercola, M. (2001). Wnt antagonism initiates cardiogenesis in *Xenopus laevis*. *Genes Dev.* **15**, 304-315.
- Terami, H., Hidaka, K., Katsumata, T., Iio, A. and Morisaki, T. (2004). Wnt11 facilitates embryonic stem cell differentiation to Nkx2.5-positive cardiomyocytes. *Biochem. Biophys. Res. Commun.* **325**, 968-975.
- Thomas, T., Yamagishi, H., Overbeek, P. A., Olson, E. N. and Srivastava, D. (1998). The bHLH factors, dHAND and eHAND, specify pulmonary and systemic cardiac ventricles independent of left-right sidedness. *Dev. Biol.* **196**, 228-236.
- Tian, Y., Cohen, E. D. and Morrisey, E. E. (2010a). The importance of Wnt signaling in cardiovascular development. *Pediatr. Cardiol.* **31**, 342-348.
- Tian, Y., Yuan, L., Goss, A. M., Wang, T., Yang, J., Lepore, J. J., Zhou, D., Schwartz, R. J., Patel, V., Cohen, E. D. et al. (2010b). Characterization and in vivo pharmacological rescue of a Wnt2-Gata6 pathway required for cardiac inflow tract development. *Dev. Cell* **18**, 275-287.
- Torres, M. A., Yang-Snyder, J. A., Purcell, S. M., DeMarais, A. A., McGrew, L. L. and Moon, R. T. (1996). Activities of the Wnt-1 class of secreted signaling factors are antagonized by the Wnt-5A class and by a dominant negative cadherin in early *Xenopus* development. *J. Cell Biol.* **133**, 1123-1137.
- Tsuchihashi, T., Maeda, J., Shin, C. H., Ivey, K. N., Black, B. L., Olson, E. N., Yamagishi, H. and Srivastava, D. (2011). Hand2 function in second heart field progenitors is essential for cardiogenesis. *Dev. Biol.* **351**, 62-69.
- Tzahor, E. (2007). Wnt/beta-catenin signaling and cardiogenesis: timing does matter. *Dev. Cell* **13**, 10-13.
- Ueno, S., Weidinger, G., Osugi, T., Kohn, A. D., Golob, J. L., Pabon, L., Reinecke, H., Moon, R. T. and Murry, C. E. (2007). Biphasic role for Wnt/beta-catenin signaling in cardiac specification in zebrafish and embryonic stem cells. *Proc. Natl. Acad. Sci. USA* **104**, 9685-9690.
- Wang, Z., Shu, W., Lu, M. M. and Morrisey, E. E. (2005). Wnt7b activates canonical signaling in epithelial and vascular smooth muscle cells through interactions with Fzd1, Fzd10, and LRP5. *Mol. Cell. Biol.* **25**, 5022-5030.
- Watanabe, Y. and Buckingham, M. (2010). The formation of the embryonic mouse heart: heart fields and myocardial cell lineages. *Ann. N. Y. Acad. Sci.* **1188**, 15-24.
- Yamaguchi, T. P., Bradley, A., McMahon, A. P. and Jones, S. (1999). A Wnt5a pathway underlies outgrowth of multiple structures in the vertebrate embryo. *Development* **126**, 1211-1223.
- Young, C. S., Kitamura, M., Hardy, S. and Kitajewski, J. (1998). Wnt-1 induces growth, cytosolic beta-catenin, and Tcf/Lef transcriptional activation in Rat-1 fibroblasts. *Mol. Cell. Biol.* **18**, 2474-2485.
- Yuan, Y., Niu, C. C., Deng, G., Li, Z. Q., Pan, J., Zhao, C., Yang, Z. L. and Si, W. K. (2011). The Wnt5a/Ror2 noncanonical signaling pathway inhibits canonical Wnt signaling in K562 cells. *Int. J. Mol. Med.* **27**, 63-69.
- Zhang, Y., Goss, A. M., Cohen, E. D., Kadzik, R., Lepore, J. J., Muthukumaraswamy, K., Yang, J., DeMayo, F. J., Whitsett, J. A., Parmacek, M. S. et al. (2008). A Gata6-Wnt pathway required for epithelial stem cell development and airway regeneration. *Nat. Genet.* **40**, 862-870.
- Zhou, W., Lin, L., Majumdar, A., Li, X., Zhang, X., Liu, W., Etheridge, L., Shi, Y., Martin, J., Van de Ven, W. et al. (2007). Modulation of morphogenesis by noncanonical Wnt signaling requires ATF/CREB family-mediated transcriptional activation of TGFbeta2. *Nat. Genet.* **39**, 1225-1234.

Table S1. PCR primers

Gene	Forward	Reverse
<i>Fik1</i>	GTGGCTTCCTGATGGCAGAA	TGTTATCATAACCTCGGCTAAAAAGTAA
<i>Tbx18</i>	TGCCGGTGGACAACAAGAGATACA	ATATGGCCTTGGTCATCCAGCTCA
<i>Tcf21</i>	TCGTTTCCGTTTCAGCGTCTCTCT	TTTCAGGGAGTCACAGTCCAGCAT
<i>Tbx5</i>	ACTGTGTTTGTGCGCTCTCTCTCT	AGACTTCCACGTTCTCAGCCACAT
<i>Pecam1</i>	ATTCCTCAGGCTCGGGTCTT	CCATGCACCTTCACCTCGTA
<i>Sm22a</i>	TCTAATGGCTTTGGGCAGTTTGGC	TTTGAAGGCCAATGACGTGCTTCC
<i>Nkx2.5 (new)</i>	ACAAAGCCGAGACGGATGG	CTGTGCTTGCACCTTGATAGC
<i>SMA/Acta2</i>	ATTGTGCTGGACTCTGGAGATGGT	TGATGTCACGGACAATCTCACGCT
<i>Mlc2v</i>	CCAGATGTTTCGCAGCCTTTC	TCAGGGCTCAGTCCTTCTCTTC
<i>Mlc2a</i>	AGGCACAACGTGGCTCTTCT	CCCATCCCTGTTCTGGTCAA
<i>cTnl</i>	AGACTGGCGCAAGAATATCGA	GACGTCCTTCAGAGCACAGTGT
<i>Isl1</i>	TAAGCATGCCCTGTAGCTGGTT	GATGGATCTCAAAAAAATGGTAAAGAG
<i>Hand1</i>	GAAGGGTTAAACCCGGTCTTTG	CAAGGCTGGAGATGACACGAA
<i>Hand2</i>	CCACCAGATACATCGCCTACCT	CTTTCACGTCGGTCTTCTTGATC
<i>Mesp1</i>	ATCCCAGGAAAGGCAGGAAATGGA	TGTGCTCAGACAGGGTGACAATCA
<i>Gapdh</i>	AGTTGTCTCCTGCGACTTCA	CCAGGAAATGAGCTTGACAAAGTT